New hope for tough hepatitis c cases: triple therapy shows promise

NCT ID NCT02647632

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measure of success was whether the virus remained undetectable 12 weeks after treatment ended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin
What this could lead to: If successful, this could offer a new treatment option for people with hepatitis C who did not get better with standard therapies.
What could go wrong: This is a small, early-phase study with only 26 participants. Results may not apply to everyone, and the combination may cause side effects or fail to clear the virus in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

ALRIC Laurent

Toulouse, 31059, France
ASSELAH Tarik

Clichy, 92110, France
BOURLIERE Marc

Marseille, 13285, France
Christophe HEZODE

Créteil, 94010, France
JEZEQUEL Caroline

Rennes, 35033, France
LARREY Dominique

Montpellier, 34295, France
LEROY Vincent

Grenoble, 38043, France
METIVIER Sophie

Toulouse, 31059, France
POL Stanislas

Paris, 75679, France
SAMUEL Didier

Villejuif, 94804, France
SERFATY Lawrence

Paris, 75571, France
TRAN Albert

Nice, 06202, France
ZOULIM Fabien

Lyon, 69317, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.